Monte Rosa Therapeutics, Inc. GLUE Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| -$38.63M— | —— | -$135.35M-24.7% | -$108.5M-46.7% | ||
| $8.36M+2.9% | $8.12M+30.5% | $6.22M+66.1% | $3.75M+79.8% | ||
| $18.87M+4.1% | $18.13M+8.7% | $16.67M+42.9% | $11.66M+124% | ||
| —— | $0— | —— | —— | ||
| —— | $6.25M+8.6% | $5.76M— | —— | ||
| $7.85M+87.7% | $4.18M+17.6% | $3.56M— | —— | ||
| -$604K— | —— | —— | $2.13M— | ||
| $7.52M-91.0% | $83.38M+66.8% | $50M— | $0— | ||
| -$1.08M+20.0% | -$1.35M-113% | $10.37M— | —— | ||
| $4.79M+1,543% | -$332K— | —— | $187K— | ||
| -$22.8M-154% | $42M— | —— | -$92.47M-55.8% | ||
| $4.7M+17.9% | $3.99M-79.1% | $19.04M+47.5% | $12.91M+32.7% | ||
| —— | —— | $88.8M— | —— | ||
| $5.72M+439% | $1.06M— | $0-100% | $20.06M— | ||
| —— | $641K— | —— | —— | ||
| $30.35M-69.3% | $98.89M+260% | $27.49M+32.9% | $20.68M-94.5% | ||
| —— | —— | $72.49M+124% | -$299.89M-192% | ||
| $8.36M+2.9% | $8.12M+30.5% | $6.22M+66.1% | $3.75M+79.8% | ||
| $7.85M+87.7% | $4.18M+17.6% | $3.56M— | —— | ||
| —— | —— | —— | —— | ||
| $7.52M-91.0% | $83.38M+66.8% | $50M— | $0— | ||
| -$1.08M+20.0% | -$1.35M-113% | $10.37M— | —— | ||
| $4.79M+1,543% | -$332K— | —— | $187K— | ||
| -$604K— | —— | —— | $2.13M— | ||
| $7M— | $0— | —— | —— | ||
| —— | —— | —— | —— | ||
| —— | —— | —— | —— | ||
| —— | —— | —— | $6.24M— | ||
| —— | —— | $188K— | —— | ||
| -$1.08M+20.0% | -$1.35M-113% | $10.37M— | —— | ||
| —— | $50M— | —— | $0— | ||
| -$27.5M-172% | $38.01M— | —— | -$105.38M-52.5% | ||
| -$27.5M-172% | $38.01M— | —— | -$105.38M-52.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Monte Rosa Therapeutics, Inc. generate?
- Monte Rosa Therapeutics, Inc. (GLUE) generated -$14.7M in operating cash flow over the trailing twelve months.
- What is Monte Rosa Therapeutics, Inc.'s free cash flow?
- After $5.0M of capital expenditures, Monte Rosa Therapeutics, Inc.'s free cash flow was -$19.7M over the trailing twelve months, down 164.5% year over year.
- Where does Monte Rosa Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Monte Rosa Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
